Výsledky vyhledávání - "B De Pascalis"

Prospective multicenter observational trial on the safety and efficacy of LEVORAG® Emulgel in the treatment of acute and chronic anal fissure

Autor: R. Digennaro, G. Pecorella, S. La Manna, A. Alderisio, B. De Pascalis, D. Pennisi, G. Santangelo, F. Pezzolla, A. Racalbuto, G. Serra, A. Pulvirenti D’Urso, D. F. Altomare

Publikováno v: Techniques in Coloproctology

Background Anal fissure (AF) is a common cause of anal pain with a tendency not to heal spontaneously because of ischemia of the anoderm caused by sphincter spasm. Lateral internal sphincterotomy, while very effective, can cause fecal incontinence an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c056fbdb154f27f9caa47fdae1da722c
http://europepmc.org/articles/PMC4555206

Zobrazit plný text záznamu

Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease

Autor: Angelo Dezi, Virginia Festa, A. Moretti, V. Tornatore, Marco Bianchi, Maurizio Koch, A. Ciaco, R. Luchetti, B. De Pascalis, M. Mangone, Claudio Papi

Publikováno v: Alimentary Pharmacology & Therapeutics. 33:902-910

Aliment Pharmacol Ther 2011; 33: 902–910 Summary Background Diverticular disease of the colon is a common gastrointestinal disease. Although most patients remain asymptomatic for their whole life, about 20–25% present symptoms related to ‘diver

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1683cb41dc3ed91eebee105865b83897
https://doi.org/10.1111/j.1365-2036.2011.04606.x

Zobrazit plný text záznamu

Plný text ve formátu HTML

Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease

Autor: M, Bianchi, V, Festa, A, Moretti, A, Ciaco, M, Mangone, V, Tornatore, A, Dezi, R, Luchetti, B, De Pascalis, C, Papi, M, Koch

Publikováno v: Alimentary pharmacologytherapeutics. 33(8)

Diverticular disease of the colon is a common gastrointestinal disease. Although most patients remain asymptomatic for their whole life, about 20-25% present symptoms related to 'diverticular disease'. Several randomised trials verified efficacy of a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::19931b9303646cfbb463e06fe466005e
https://pubmed.ncbi.nlm.nih.gov/21366632

Zobrazit plný text záznamu

Plný text ve formátu HTML

Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease

Autor: Domenico Melina, Francesca Schinzari, Alessandro Armuzzi, Manfredi Tesauro, Nadia Mores, Carmine Cardillo, B De Pascalis

This study assessed the presence of endothelial dysfunction in patients with inflammatory bowel diseases (IBDs) and evaluated the possible role of tumor necrosis factor (TNF)-alpha in the pathophysiology of this abnormality. Similar elevations in cir

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1629a9c33b77217d0872980f0fe850b
http://hdl.handle.net/2108/55877

Zobrazit plný text záznamu

Infliximab in Crohn's disease: early and long-term treatment

Autor: F. De Vincentis, P. Fedeli, Antonio Gasbarrini, Alessandro Armuzzi, B. De Pascalis

The natural history of Crohn's disease is characterized by a remitting and relapsing course that progresses to complications and surgery in the majority of patients. Current treatment guidelines advocate a stepwise approach according to disease locat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78eb5612f3d749a060f89fc8fc6c36e7
http://hdl.handle.net/10807/22534

Zobrazit plný text záznamu

Sacroileitis and peripheral arthropathy associated with ulcerative colitis: effect of infliximab on both articular and intestinal symptoms

Autor: A, Lupascu, A, Armuzzi, B, De Pascalis, E, Carloni, E C, Lauritano, A, Gasbarrini, P, Pola

Publikováno v: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 36(6)

Infliximab has been proven to be an effective therapy in a miscellany of rheumatic diseases and has been approved for the treatment of moderate-to-severe Crohn's disease with an inadequate response to conventional therapy and for the management of en

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fcf656b6e2572ca1de2c95836cbf4a89
https://pubmed.ncbi.nlm.nih.gov/15248384

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání